SEPTInvestingStart Free

ABOS 8-K: SEC filing

Acumen Pharmaceuticals

Filed with the SEC on · accession 0001628280-26-070987

ABOS filed a 8-K (current report) with the SEC on Nov 5, 2026. Acumen Pharmaceuticals announced a restructuring that will cut approximately 90% of its workforce (52 employees) and terminated its $50 million loan agreement with K2 HealthVentures by prepaying approximately $23.3 million in cash. The stock moved -1.2% by the first close after the filing.

Summary of the filing

Acumen Pharmaceuticals announced a restructuring that will cut approximately 90% of its workforce (52 employees) and terminated its $50 million loan agreement with K2 HealthVentures by prepaying approximately $23.3 million in cash. The moves follow the company's decision to cease development of sabirnetug and evaluate strategic options.

For details, click here →How to read a 8-K →

Key details

Loan payoff amount (principal, interest, final payment fee, expenses)$23.3M
Original term loan facility aggregate principal amount$50.0M
First tranche borrowed$30.0M
Final payment fee$1.6M
Estimated restructuring costs (severance and related)$7.8M
RegistrantAcumen Pharmaceuticals, Inc.
Lender whose loan agreement was terminatedK2 HealthVentures LLC

How ABOS stock reacted

Close before

$0.22

Nov 4, 2026

First close after

-1.16%

$0.21

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ABOS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ABOS?

Click here

Frequently asked questions

What did ABOS file with the SEC on Nov 5, 2026?

ABOS filed a 8-K (SEC filing). Acumen Pharmaceuticals announced a restructuring that will cut approximately 90% of its workforce (52 employees) and terminated its $50 million loan agreement with K2 HealthVentures by prepaying approximately $23.3 million in cash. The moves follow the company's decision to cease development of sabirnetug and evaluate strategic options.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did ABOS stock react to this filing?

ABOS closed at $0.22 before the filing and $0.21 on Nov 5, 2026 (-1.16%).

Other ABOS SEC filings

Get alerts when ABOS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ABOS overviewABOS analysisABOS newsLatest SEC filings